Wedbush Reiterates Neutral on CytomX Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated a Neutral rating on CytomX Therapeutics (NASDAQ:CTMX) and maintained a $3 price target on the stock.

March 12, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Robert Driscoll reiterated a Neutral rating on CytomX Therapeutics and maintained a $3 price target.
The reiteration of a Neutral rating and maintenance of a $3 price target by a reputable analyst like Robert Driscoll could influence investor sentiment but is unlikely to cause significant short-term price movement given the lack of change in the rating or target price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100